Infliximab neutralizes soluble TNF-α, blocking TNF receptor signaling but not engaging target cells; it does not directly kill TNF-producing cells. Direct cytotoxicity (e.g., ADCC/apoptosis) occurs only when binding transmembrane TNF, not the soluble form.